Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Experimental antivenom against serine proteases from the Bothrops jararaca venom obtained in mice, and its comparison with the antibothropic serum from the Butantan Institute

Full text
Kuniyoshi, Alexandre Kazuo [1] ; Kodama, Roberto Tadashi [1] ; Cajado-Carvalho, Daniela [1] ; Iwai, Leo Kei [2] ; Kitano, Eduardo [2] ; Fernandes da Silva, Cristiane Castilho [1] ; Duzzi, Bruno [1] ; da Silva, Wilmar Dias [1] ; Portaro, Fernanda Calheta [1]
Total Authors: 9
[1] Butantan Inst, Immunochem Lab, Av Prof Vital Brazil 1500, BR-05503900 Sao Paulo, SP - Brazil
[2] Butantan Inst, Ctr Toxins Immune Response & Cell Signaling CeTIS, Special Lab Appl Toxinol, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Toxicon; v. 169, p. 59-67, NOV 2019.
Web of Science Citations: 0

In Brazil, snakes from the Bothrops genus are responsible for thousands of accidents, and their venoms are mainly made up of proteolytic enzymes. Although the antibothropic serum produced by the Butantan Institute is remarkable in saving lives, studies show that some symptoms observed in cases of envenoming are not efficiently neutralized. Moreover, our group has shown that the commercial antivenom does not fully neutralize in vitro some serine proteases present in the Bothrops jararaca venom. Therefore, this study focuses on a new method in the production of specific immunoglobulins capable of neutralizing the activities of these enzymes in vitro. For this, a pool of serine proteases that was not inhibited by the commercial antivenom, made up of four enzymes (KN-BJ2, BjSP, HS112 and BPA) from the B. jararaca venom was obtained through two chromatographic steps (DEAE-HPLC and C8-RP-HPLC). The identities of these proteases were confirmed by SDS-PAGE, followed by tryptic digestion and mass spectrometry analysis. This pool was inoculated into BALB/c and C57BL/6 mice, using SBA-15 as adjuvant, and the produced IgGs were purified by affinity chromatography. The sera were characterized by ELISA, avidity and proteolytic neutralization assays. Both animal models responded to the immunization, producing higher IgGs titers when compared to the commercial antivenom. The experimental serum from BALB/c mice presented a better hydrolysis inhibition of the selective fluorescent substrate for serine proteases (similar to 80%) when compared to C57BL/6 (similar to 25%) and the commercial antivenom ( < 1%) at the dose of 500:1 (weight of antivenom:weight of venom). These results show that a different immunization method using isolated serine proteases improves the toxins neutralizing efficacy and could lead to a better end product to be used as a supplemental medicine to the currently used immunotherapy. (AU)

FAPESP's process: 15/13124-5 - Purification and characterization of peptides present in the venom of African snakes: searching for peptidase inhibitor of medical importance
Grantee:Roberto Tadashi Kodama
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 13/07467-1 - CeTICS - Center of Toxins, Immune-Response and Cell Signaling
Grantee:Hugo Aguirre Armelin
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 13/15344-7 - Efficacy of the bothropic antivenom from Butantan Institute: obtention, characterization and neutralization of serinepeptidases from the venom of Bothrops jararaca
Grantee:Alexandre Kazuo Kuniyoshi
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 12/06677-0 - Study of peptidase activity of the B. jararaca venom and potential neutralizing serum produced at Instituto Butantan upon this activity: new aspects of Bothrops poisoning
Grantee:Fernanda Calheta Vieira Portaro
Support Opportunities: Regular Research Grants
FAPESP's process: 15/15364-3 - Toxic potential analysis of proteases and peptides present in scorpion Tityus serrulatus venom and the blockage capacity of commercial antivenoms: Enhancing the knowledge of venom and its mechanism of action.
Grantee:Fernanda Calheta Vieira Portaro
Support Opportunities: Regular Research Grants